Summary:
- Genenta, a biotechnology company, has announced the pricing of a $15 million registered direct offering of American Depositary Shares (ADSs).
- The offering will allow Genenta to raise funds to support the development of its gene therapy platform, which aims to treat various types of cancer.
- The successful completion of this offering will provide Genenta with additional resources to advance its clinical research and bring its innovative cancer treatments closer to patients in need.